J.P. Morgan analyst Anupam Rama has maintained their neutral stance on SRPT stock, giving a Hold rating today.
Claim 55% Off TipRanks
Forget margin or options. Here's how the pros trade SRPTAnupam Rama has given his Hold rating due to a combination of factors tied to Sarepta’s current performance and future outlook. The company delivered first-quarter revenue above expectations, led by stronger-than-anticipated Elevidys sales while the PMO franchise matched consensus and full-year revenue guidance was maintained, underscoring a stable but not dramatically accelerating commercial trajectory.
At the same time, Rama highlights that a more constructive stance likely requires clearer evidence of sustained commercial momentum and successful advancement of the pipeline. Key upcoming readouts, including mid-stage data for SRP-1001 in FSHD and SRP-1003 in DM1 expected in the second half of 2026, could improve sentiment, but these programs still carry execution and clinical risk, leading to a balanced, Neutral positioning on SRPT shares for now.
In another report released today, TD Cowen also maintained a Hold rating on the stock with a $17.00 price target.
SRPT’s price has also changed moderately for the past six months – from $17.640 to $23.030, which is a 30.56% increase.